Richard Lesniewski
Fondateur chez Madison Vaccines, Inc.
Profil
Richard R.
Lesniewski is the founder of Madison Vaccines, Inc., which was founded in 2012.
He holds the title of President, Chief Executive Officer & Director at Madison Vaccines, Inc. Currently, Dr. Lesniewski is a Director at Scarab Genomics LLC and DNASTAR, Inc. In the past, he was a Director-Cancer Research at Abbott Laboratories from 1983 to 2009 and a Vice President-Oncology Biopharmaceuticals at GSK Plc.
Postes actifs de Richard Lesniewski
| Sociétés | Poste | Début |
|---|---|---|
Madison Vaccines, Inc.
 Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Fondateur | 01/01/2012 |
DNASTAR, Inc.
 DNASTAR, Inc. Packaged SoftwareTechnology Services DNASTAR, Inc. is a bioinformatics software company that has been innovating since 1984. The private company is based in Madison, WI. The company's flagship product, Lasergene, provides a comprehensive software solution for life science researchers. | Directeur/Membre du Conseil | - |
Scarab Genomics LLC
 Scarab Genomics LLC BiotechnologyHealth Technology Scarab Genomics LLC specializes in providing the most robust bacterial fermentation host for general/routine recombinant protein expression and nucleic acid production. The private company is based in Madison, WI and was founded by Trevor M. Twose. The company's Clean Genome® technology reduces the mutation rate to almost zero, even under the most stressful conditions. Scarab Genomics offers Clean Genome® LowMut T7, which provides a T7 promoter in the genome for clients wishing to use this expression option rather than the recommended synthetic T5 promoter in the pSX2 vector. Scarab Genomics also offers an insertion sequence (IS) detection kit that tests for the presence of all known E. coli IS elements in any DNA sample of interest. | Directeur/Membre du Conseil | - |
Anciens postes connus de Richard Lesniewski
| Sociétés | Poste | Fin |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/2009 |
| GSK PLC | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Scarab Genomics LLC
Scarab Genomics LLC BiotechnologyHealth Technology Scarab Genomics LLC specializes in providing the most robust bacterial fermentation host for general/routine recombinant protein expression and nucleic acid production. The private company is based in Madison, WI and was founded by Trevor M. Twose. The company's Clean Genome® technology reduces the mutation rate to almost zero, even under the most stressful conditions. Scarab Genomics offers Clean Genome® LowMut T7, which provides a T7 promoter in the genome for clients wishing to use this expression option rather than the recommended synthetic T5 promoter in the pSX2 vector. Scarab Genomics also offers an insertion sequence (IS) detection kit that tests for the presence of all known E. coli IS elements in any DNA sample of interest. | Health Technology |
DNASTAR, Inc.
DNASTAR, Inc. Packaged SoftwareTechnology Services DNASTAR, Inc. is a bioinformatics software company that has been innovating since 1984. The private company is based in Madison, WI. The company's flagship product, Lasergene, provides a comprehensive software solution for life science researchers. | Technology Services |
Madison Vaccines, Inc.
Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Health Technology |
